A Phase 2 interventional study of DE-127 Ophthalmic Solution low dose and DE-127 Ophthalmic Solution medium dose in Myopia, sponsored by Santen Pharmaceutical Co., Ltd.. Completed at 1 site in Singapore. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-08-26.
Sponsored by Santen Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Myopia with a site in Singapore — 11 open to participants now, 16 under way, 2 of them phase 3. Myopia · Singapore.
Among the 43 studies in Myopia with a site in Singapore, this one is the 16th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2017, is the only one in phase 2, and was the 18th registered.
1,163 studies on the registry are indexed under Myopia; 227 are open to participants now.
Browse Myopia studies →11 of the 43 studies in Myopia with a site in Singapore are open now. Recruiting first, the newest first:
Essilor International · Sites in Singapore
Ages 6–13
Singapore Eye Research Institute · Sites in Singapore
Ages 21+
Rodenstock GmbH · Sites in Singapore
Ages 6–12 · Healthy volunteers
Essilor International · Sites in Singapore
Ages 6–11
National University of Singapore · Sites in Singapore
Ages 7–10 · Healthy volunteers
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 120 Myopia studies recruiting now, 19 (16%) set no upper age limit and 100 (83%) stop at 75 or younger; 84 take children under 18; 52 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 5
First in 2002; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 79 across 927 interventional studies indexed under Myopia.
Median enrollment 80 across the 35 interventional studies, 150 across the 5 observational. Of the 25 that completed or were terminated, 4 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 43 have an industry lead sponsor. The 10 most frequent:
Santen Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 1 is open to participants now.
Santen Pharmaceutical Co., Ltd. has 2 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
7 of the studies in Myopia with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06816446Rodenstock GmbHInfluence of Rodenstock Spectacle Lenses on Myopia Progression. | 2026-12 |
| NCT06717035Singapore National Eye CentreEvaluation of Performance of MiYOSMART Photochromic and Clear Spectacle Lenses in Myopic Children | 2027-01-02 |
| NCT06631339National University of SingaporeOptimizing Light Exposure for Myopia Prevention and Control (LightSPAN) | 2027-01-26 |
| NCT07505264Singapore Eye Research InstituteComparison of Myopic Small Incision Lenticule Extraction (SMILE) With VISUMAX 500 Versus VISUMAX 800 Platforms | 2027-05 |
| NCT07779941Singapore National Eye CentreA Pilot Evaluation of Refractive Error Progression in Pre-Myopic Children in Singapore With and Without Myopia Control Spectacles | 2027-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 43 studies in Myopia with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the safety and efficacy of three concentrations of DE-127 ophthalmic solution when compared to Placebo in subjects diagnosed with mild or moderate myopia.
To investigate the dose response of DE-127.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: DE-127 Ophthalmic Solution low dose
Drug: DE-127 Ophthalmic Solution medium dose
Drug: DE-127 Ophthalmic Solution high dose
Drug: Placebo Ophthalmic Solution
Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
Placebo Ophthalmic Solution dosed once daily for 12 months
Spherical equivalent
Change from Baseline in spherical equivalent determined by cycloplegic autorefraction at Month 12 in the study eye.
Time frame: Month 12
Ran from Oct 2017 to primary completion in Sep 2019, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Santen Pharmaceutical Co., Ltd. →